LLY
T13.0% portfolioEli Lilly and Company
OverviewEli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide, primarily focusing on diabetes, obesity, cancer, and immunology. Revenue
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide, primarily focusing on diabetes, obesity, cancer, and immunology. Revenue is increasingly driven by its leading weight-loss and diabetes drugs, Mounjaro and Zepbound. The company sells to pharmaceutical wholesalers, healthcare providers, and government programs, while expanding direct-to-patient sales via its LillyDirect platform.
- What They Do (Plain English & Analogies)
- Eli Lilly and Company is like a high-end software company for the human body. Instead of writing computer code, they develop biological instructions (drugs) that tell the body how to fix metabolic errors (like diabetes and obesity), clear out neural 'clutter' (such as Alzheimer's disease), or fight internal 'security breaches' (like cancer). They discover, develop, and sell medicines globally, with a significant focus on life-changing treatments for chronic conditions. Their current success with weight-loss and diabetes drugs is akin to Apple launching the iPhone, creating a revolutionary product category that is fundamentally changing how society manages metabolic health.
- Very Brief History
- Founded in 1876 by Colonel Eli Lilly in Indianapolis, Eli Lilly and Company became a global pharmaceutical leader by being the first to mass-produce penicillin and insulin. Over the last century, it evolved from a traditional chemical drug maker into a biotechnology powerhouse. Key milestones include the launch of Prozac in the 1980s, which revolutionized psychiatry, and the recent 2020s pivot to 'incretin' science (Mounjaro/Zepbound), which has made it one of the most valuable healthcare companies in the world by market capitalization.
- "Street Stereotype"
- The 'Growth King' of Big Pharma. Lilly is generally perceived by investors more like a high-growth Silicon Valley tech stock than a traditional, slow-moving pharmaceutical company. Analysts view it as the gold standard for innovation in the obesity and Alzheimer's markets, often trading at a significant premium to its peers because of its massive 'moat' in manufacturing and its industry-leading pipeline.
- Subsidiaries On Linked In*
- Loxo Oncology at Lilly — LinkedIn: Loxo-Oncology-at-Lilly
- Prevail Therapeutics — LinkedIn: prevail-therapeutics
- Akouos — LinkedIn: akouos
- Mablink Bioscience — LinkedIn: mablink-bioscience
- Versanis Bio — LinkedIn: versanis-bio
- Sigilon Therapeutics — LinkedIn: sigilon-therapeutics
- Dice Therapeutics — LinkedIn: dice-therapeutics
- Point Biopharma — LinkedIn: point-biopharma
- Ventix Biosciences — Acquisition completed; LinkedIn: ventix-biosciences
- Ajax Therapeutics — Acquisition announced April 2026; LinkedIn: ajax-therapeutics
- Kelonia Therapeutics — Acquisition announced April 2026; LinkedIn: kelonia-therapeutics
- Centessa Pharmaceuticals — Acquisition announced April 2026; LinkedIn: centessa-pharmaceuticals
- Orna Therapeutics — Acquisition announced April 2026; LinkedIn: orna-therapeutics
- Customer Sectors & Example Clients
- Lilly's primary customers are healthcare providers and patients. Their 'clients' in the business sense are the massive intermediaries that control drug distribution. These include: 1. Pharmaceutical Wholesalers (e.g., McKesson, AmerisourceBergen, Cardinal Health); 2. Pharmacy Benefit Managers/Payers (e.g., CVS Health/Caremark, UnitedHealth Group/OptumRx, Cigna/Express Scripts); 3. Government Entities (Medicare and Medicaid); and 4. Direct-to-Consumer (via the LillyDirect platform).
- New Customers / Segments They'Re Targeting
- Eli Lilly is aggressively targeting new customer segments by expanding access to its obesity medicines, notably through an agreement with the US government to provide Medicare and Medicaid access with a $50 out-of-pocket cap, effective no later than July 1, 2026. They are also focused on 'sidelined' patients who have been waiting for an oral option for weight management, anticipating the launch of Orforglipron to expand this market. Furthermore, Lilly is exploring new indications for its incretin portfolio, including substance use disorders (alcohol and tobacco use disorder), psychiatric conditions (bipolar disorder, major depressive disorder), sleep apnea, peripheral artery disease, hypertension, and osteoarthritis of the knee, aiming to reach patients with these comorbidities. The direct-to-patient platform, LillyDirect, is also a key channel for reaching new patients directly.
- Supply Chain And Sourcing Geographies
- Eli Lilly operates a global supply chain with a significant focus on expanding its manufacturing capabilities. The company has committed over $55 billion since 2020 to a massive manufacturing build-out, the largest in its history. This includes plans to build multiple new manufacturing sites in the US, with new facilities already operational in Wisconsin and North Carolina. Additionally, manufacturing expansion efforts are underway in Europe. The company aims to increase its incretin dose production significantly, having exceeded its goal to produce 1.8 times the number of incretin doses in 2025 compared to 2024.
- Sales Geographies And Expansion Plans
- Eli Lilly sells its products worldwide. In 2025, Mounjaro completed its international rollout, driving double-digit volume growth in Europe, Japan, and China, and doubling volume in the rest of the world. The company is now the incretin share of market leader outside the US as well. For Orforglipron, submissions for obesity have been made in the US and over 40 countries globally, with launches expected in the US during 2026 and in most international markets during 2027, with a few exceptions like the UAE potentially seeing launches in late 2026. The company is also leaning in to gain reimbursement for Mounjaro in more countries for type 2 diabetes, currently reimbursed in nine, including China with its NRDL listing.
- How Key Themes May Help/Hurt
- The 'GLP-1 Drug Producer' theme significantly helps Eli Lilly. The strong clinical evidence for GLP-1 drugs in treating obesity and other comorbid conditions drives increased adoption and expands the addressable market. The development of oral GLP-1 formulations like Orforglipron is expected to significantly increase patient compliance and market penetration by reaching patients who prefer pills. Ongoing expansion of indications for GLP-1 drugs into areas like NASH, Alzheimer's, immunology, substance use disorders, and psychiatric conditions could further boost market growth and revenue streams. Lilly's massive manufacturing scale-up also positions it to capitalize on this demand. However, the theme also presents potential challenges. Increased competition from new entrants like Amgen and Viking Therapeutics, alongside existing rivals like Novo Nordisk, could lead to market share erosion. Regulatory scrutiny concerning long-term side effects and pricing pressures, particularly from government entities like Medicare and Medicaid, could impact profitability and market dynamics. While Lilly is investing heavily, supply chain constraints, especially for autoinjectors, could still limit the ability to meet rising demand efficiently.
3 Main Long-Term Bull Details
- Oral GLP-1 Dominance and Market Expansion: The upcoming launch of Orforglipron (oral GLP-1) is expected to unlock a 'mass market' of patients who prefer a pill over an injection, significantly expanding the total addressable market beyond current injectable users. 2. Peerless Pipeline and Diversification: Beyond current blockbusters, Lilly boasts a robust pipeline including the triple-agonist Retatrutide, which has shown record-breaking 29% weight loss in Phase 3 trials, positioning it as a future gold standard. The company is also successfully diversifying into high-value therapeutic areas like Alzheimer's (Kisanlo, which has captured over 50% of the US amyloid-targeting market) and revitalizing oncology and immunology portfolios with 'incretin-plus' combinations. 3. Massive Manufacturing Moat: A $55 billion manufacturing investment since 2020 has enabled a 1.8x annual increase in incretin dose production, creating a significant barrier to entry for competitors and ensuring Lilly can meet global demand. This capacity also supports aggressive pursuit of broad access, including the landmark July 2026 Medicare/Medicaid rollout.
3 Main Long-Term Bear Details
- Significant Pricing Pressure: Management has guided for an acceleration in price erosion to the 'low-to-mid teens' for 2026, reflecting the high cost of securing broad Medicare access and China NRDL inclusion. If volume growth fails to sufficiently offset these realized price declines, or if gross margins contract further due to new manufacturing facility startup costs, Lilly may struggle to maintain its premium valuation. 2. Intensifying Competition and Cannibalization Risk: While management views oral GLP-1s as market-expansive, the entry of multiple competitors (including Novo's oral Wegovy) could lead to aggressive rebate wars and market share erosion. Furthermore, the rapid succession of Lilly's own products (Zepbound to Orforglipron to Retatrutide) creates a risk of internal cannibalization, potentially shortening the peak revenue window for individual brands. 3. Regulatory and Safety Scrutiny: The expansion into Medicare and Medicaid invites intense government scrutiny over long-term pricing and safety. Any safety signals emerging from the broader real-world use of incretins, or changes in state-level Medicaid coverage (as seen in California removing obesity coverage), could disrupt the growth trajectory. Additionally, the heavy reliance on direct-to-patient platforms like LillyDirect may face regulatory pushback regarding pharmacy distribution norms and fair competition.
- Competitors And Differentiation
- Eli Lilly's primary competitor in the metabolic health market is Novo Nordisk, with products like Wegovy and oral semaglutide. In oncology, they compete with various companies offering BTK inhibitors and other cancer therapies. In Alzheimer's, they compete in the amyloid-targeting therapy space. Lilly differentiates itself through several key strategies: 1. **Superior Efficacy and Pipeline:** Lilly's tirzepatide (Mounjaro, Zepbound) is a dual GLP-1 and GIP receptor agonist, which has shown superior weight loss compared to single GLP-1 agonists like semaglutide. Their pipeline includes next-generation oral GLP-1 (Orforglipron) and a triple agonist (Retatrutide) with record-breaking weight loss data. 2. **Manufacturing Scale:** A massive $55 billion investment in manufacturing capacity creates a significant barrier to entry and ensures Lilly can meet global demand. 3. **Market Expansion:** Lilly aims to expand the total addressable market by targeting new patient populations (e.g., those preferring oral options, Medicare/Medicaid beneficiaries) and new indications beyond obesity. 4. **Consumer-Centric Approach:** Through platforms like LillyDirect, they are reducing friction in patient access and exploring new pricing models. 5. **Diversified Portfolio and AI Investment:** Reinvesting in immunology, neuroscience, and oncology, and leveraging AI collaborations (e.g., with NVIDIA) to accelerate drug discovery.
- Recent Performance & What The Market'S Focused On
- Eli Lilly delivered robust financial performance in 2025, with full-year revenue growing 45% compared to 2024 to $65.2 billion, and Q4 2025 revenue increasing 43% compared to Q4 2024, driven by key products like Mounjaro and Zepbound. The company provided strong 2026 revenue guidance of $80 billion to $83 billion, representing a 25% increase at the midpoint compared to 2025. The market is primarily focused on the success of the upcoming Orforglipron launch in the US (expected Q2 2026) and whether it will expand the market or cannibalize existing injectable sales. Investors are also closely watching how Lilly navigates the guided 'low-to-mid teens' price erosion in 2026 due to Medicare access and China NRDL, and if volume growth can sufficiently offset these headwinds. Key metrics being tracked include the implementation of Medicare/Medicaid obesity coverage by July 1, 2026, and the data readouts from the six remaining Phase 3 trials for Retatrutide throughout 2026.
- Revenue Segments And Estimated Mix
- Product — Mix: 93.52%; Source: FY2025 financial results; Trend: Increased 49.6% compared to 2024
- Collaboration and Other Revenue — Mix: 6.48%; Source: FY2025 financial results; Trend: Decreased -1.72% compared to 2024
- Key Products (Mounjaro, Zepbound, Eblis, Inlureo, Jayperca, Kisanlo, Omvo, Verzenio) — Mix: Over $13 billion in Q4 2025; Source: Q4 2025 earnings call; Trend: Grew 91% compared to Q4 2024
- Cardiometabolic Health — Mix: Largest segment; Source: Existing knowledge, driven by Mounjaro and Zepbound; Trend: Strong growth
- Oncology — Mix: n/m; Source: Existing knowledge
- Immunology — Mix: n/m; Source: Existing knowledge
- Neuroscience — Mix: n/m; Source: Existing knowledge
- Product Brands
- Basaglar
- Humalog
- Humalog Mix 75/25
- Humalog U-100
- Humalog U-200
- Humalog Mix 50/50
- insulin lispro
- insulin lispro protamine
- insulin lispro mix 75/25
- Humulin
- Humulin 70/30
- Humulin N
- Humulin R
- Humulin U-500
- Jardiance
- Trajenta
- Trulicity
- Alimta
- Cyramza
- Erbitux
- Retevmo
- Tyvyt
- Verzenio
- Olumiant
- Taltz
- Cymbalta
- Emgality
- Zyprexa
- Bamlanivimab
- Etesevimab
- Bebtelovimab
- Cialis
- Forteo
- Inlureo
- Omvo
- Jayperca
- Mounjaro
- Kisanlo
- Orforglipron
- Retatrutide
- Oloralintide
- Brenepatide
- Zepbound
- Eblis
- Talsa
- Pirtobrutinib
- Imlunestrant
- Sofetibart
- Mepetekcan
- Tirsolecimid
- Vepubratinib
- Donanemab
- Kwikpen
Bull / Bear DetailsAs of July 22, 2026, Lilly remains the premier growth play in biopharma, transitioning to dominant volume-driven market expansion. Despite guided low-to-mid-tee
Thesis
As of July 22, 2026, Lilly remains the premier growth play in biopharma, transitioning to dominant volume-driven market expansion. Despite guided low-to-mid-teen price erosion in 2026, the successful Koundeo launch, robust Q1 performance, and increased revenue guidance validate its strategy. A peerless pipeline, including Retatrutide and diversification into Alzheimer's, immunology, and neuroscience, reinforces the bullish case.
Bull case
The metabolic franchise is rapidly expanding with the successful Q1 2026 launch of oral Koundeo, attracting 80% new-to-class patients and securing early PBM access. Positive Phase III data for Koundeo (CV safety) and Retatrutide (profound A1c reduction, significant weight loss) further solidify Lilly's multi-modality leadership and market expansion potential beyond injectables.
Lilly delivered robust Q1 2026 revenue growth of 56% and raised its full-year 2026 revenue guidance to $82B-$85B, reflecting strong Mounjaro/Zepbound performance and early Koundeo uptake. This demonstrates effective execution of its volume-over-price strategy, supported by massive manufacturing investments and the July 2026 Medicare GLP-1 bridge program.
Beyond obesity, Lilly is diversifying into high-value therapeutic areas with significant pipeline progress. Positive Phase III data for Eblis (pediatric AD) and Pirtobrutinib (CLL), along with new Phase III programs for Eloralintide and Brenepatide, and strategic acquisitions in immunology, oncology, and neuroscience, ensure sustainable long-term growth drivers.
Bear case
The strategic shift to 'volume-over-price' introduces significant financial risks, with management guiding for low-to-mid-teen price erosion in 2026. Q1 2026 saw a 7% U.S. price decline and a 1 percentage point gross margin contraction, highlighting that if volume growth fails to sufficiently offset these realized price declines, profitability could be pressured.
While Koundeo is market-expansive, the rapid succession of Lilly's own products (Zepbound, Koundeo, Retatrutide, Eloralintide) creates a risk of internal cannibalization, potentially shortening the peak revenue window for individual brands. Intensifying competition from other oral GLP-1s could also lead to aggressive rebate wars and market share erosion.
The expansion into Medicare and Medicaid invites intense government scrutiny over long-term pricing and safety. The Medicare GLP-1 bridge program extends to 2027, but future access beyond that remains subject to negotiation. Changes in state-level Medicaid coverage and potential regulatory pushback on direct-to-patient platforms like LillyDirect also pose risks.
Bull / Bear Case
- Bear Case
- Despite strong top-line growth, Eli Lilly faces significant financial risks due to its strategic shift to 'volume-over-price'. Management's guidance for low-to-mid-teen price erosion in 2026, evidenced by a 7% U.S. price decline and 1 percentage point gross margin contraction in Q1 2026, could pressure profitability if volume growth doesn't sufficiently compensate. The rapid succession of Lilly's own GLP-1 products (Zepbound, Koundeo, Retatrutide, Eloralintide) creates a risk of internal cannibalization, potentially shortening peak revenue windows. Intensifying competition from other oral GLP-1s and increased government scrutiny over long-term pricing and safety, particularly with Medicare/Medicaid expansion and potential regulatory pushback on LillyDirect, pose further headwinds to sustained premium valuation. [cite: NEWLY GENERATED Ticker_BullBearDetails, 0]
- Bull Case
- Eli Lilly is poised for continued industry-leading growth, driven by its dominant metabolic franchise. The successful Q1 2026 launch of oral Koundeo, attracting 80% new-to-class patients and securing early PBM access, is expanding the addressable market beyond injectables. Positive Phase III data for Koundeo (CV safety) and Retatrutide (profound A1c reduction, significant weight loss) solidify Lilly's multi-modality leadership. Robust Q1 2026 revenue growth of 56% and raised full-year guidance to $82B-$85B validate its volume-over-price strategy, supported by massive manufacturing investments and the July 2026 Medicare GLP-1 bridge program. Diversification into high-value therapeutic areas like immunology, oncology, and neuroscience through pipeline progress and strategic acquisitions ensures sustainable long-term growth. [cite: NEWLY GENERATED Ticker_BullBearDetails]
- More Compelling & Why
- Bear. Eli Lilly's current P/E ratio of approximately 70-80x (TTM) is significantly higher than the pharmaceutical industry average, indicating a highly stretched valuation that prices in substantial future growth. The strongest bear argument is the guided low-to-mid-teen price erosion in 2026, coupled with Q1 2026 gross margin contraction, which highlights significant profitability risks if volume growth fails to sufficiently offset these price declines and rising expenses. A sustained period where realized price erosion is significantly less than the guided low-to-mid-teens (e.g., less than -5%), or a substantial increase in free cash flow yield to above 2.5%, would flip my view to bullish.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Manufacturing Output (Incretin Doses) for FY 2026 | Lilly's $55 billion manufacturing scale-up is a critical competitive moat, enabling it to meet surging global demand for incretins and capitalize on market expansion opportunities, ensuring supply for its 'volume-over-price' strategy. | Management's updated 'dose multiplier' target for FY 2026 (expected to be 1.5x-1.8x again). Operational status and commercial production announcements for new sites in Wisconsin and North Carolina. | Announcement of new sites reaching 'commercial production' status = Bullish; Exceeding the FY 2026 dose multiplier target = Bullish; Any manufacturing 'Form 483' or warning letters from FDA = Bearish. | Lilly's earnings calls (Q1, Q2, Q3 2026), company press releases, SEC filings (Form 10-K, 10-Q). | Local news reports on new manufacturing plant openings/expansions. Industry publications on pharmaceutical manufacturing capacity. | Supply chain intelligence platforms (e.g., Resilinc, Everstream Analytics) for manufacturing site updates. |
| Implementation of Medicare/Medicaid Obesity Coverage | This agreement significantly expands access to Lilly's obesity medicines for millions of Americans, particularly seniors, driving substantial volume growth and reinforcing the 'consumerization' of pharma through a $50 out-of-pocket cap. | Official CMS implementation date (target: July 1, 2026). Monitor volume growth in the Medicare Part D segment in Q3 2026 results. Watch for the percentage of Lilly Direct Medicare patients (expected 10-20%) transitioning to Medicare coverage. | Successful implementation by July 1, 2026 = Bullish; Volume growth in Medicare segment >25% QoQ in Q3 2026 = Bullish; Realized price erosion exceeding 15% without 2x volume offset = Bearish. | CMS announcements, Lilly's Q3 2026 earnings call, company press releases. | Government websites (CMS.gov) for policy updates. News articles on Medicare Part D coverage changes. | Claims data providers (e.g., Definitive Healthcare, IQVIA) for Medicare Part D prescription volumes for LLY obesity drugs. |
| Retatrutide (Triple Agonist) Phase 3 Data Readouts | Retatrutide's strong efficacy (29% weight loss in TRIUMPH-4) positions it as a potential future gold standard. Further positive data from the remaining 6 Phase 3 trials will solidify Lilly's long-term leadership and pipeline strength in metabolic health. | Data readouts for the 6 remaining Phase 3 trials throughout 2026 (TRIUMPH obesity program and Transcend type 2 diabetes program). Specifically, look for mean weight loss percentages exceeding 25% and discontinuation rates due to GI issues (target <10%) across the broader patient population. | Mean weight loss >25% across trials = Bullish; Discontinuation rates >15% due to adverse events = Bearish; Successful readout of the core TRIUMPH program supporting submissions for overweight/obesity, obstructive sleep apnea, and osteoarthritis of the knee in 2026 = Bullish. | Company press releases, medical conference presentations (e.g., ADA, EASD, Obesity Week), peer-reviewed journal publications, Lilly's earnings calls. | ClinicalTrials.gov for trial status updates. Medical news outlets for conference coverage. | EvaluatePharma: Pipeline analysis and consensus forecasts. Citeline (Informa): Clinical trial intelligence. |
| US Realized Price Change for 2026 | Management guided to 'low-to-mid teens' price erosion in 2026 due to strategic concessions for Medicare access and China NRDL. Monitoring this metric is crucial to assess if volume growth sufficiently offsets price declines to maintain revenue and margin. | Q1 and subsequent quarterly earnings reports for the reported US Realized Price Change. Compare against the 'low-to-mid teens' guidance (e.g., -10% to -15%). | US Realized Price Change reported as less negative than -9% (i.e., better than low-to-mid teens) = Bullish; US Realized Price Change reported as more negative than -15% (i.e., worse than low-to-mid teens) = Bearish. | Lilly's Q1, Q2, Q3 2026 earnings calls and financial statements (Form 10-Q). | Financial news outlets covering Lilly's earnings reports. | Bloomberg Terminal/Refinitiv Eikon: Analyst consensus estimates for price impact. |
| FDA Approval and US Launch of Orforglipron (Oral GLP-1) | Orforglipron is expected to expand the obesity market by appealing to patients who prefer oral medication over injectables, driving significant new volume growth for Lilly. This validates the 'market expansion' thesis and Lilly's multi-modality platform strategy. | FDA approval decision for obesity in Q2 2026. Monitor initial prescription (NBRx) ramp in the first 8 weeks post-launch compared to the Zepbound launch trajectory. Watch for the announced entry price, expected to be similar to oral semaglutide. | FDA approval by June 30, 2026 = Bullish; Any regulatory delay or 'Complete Response Letter' (CRL) = Bearish; Initial 8-week NBRx exceeding 20,000 scripts = Bullish. | Company press releases, FDA announcements, Lilly's Q2 2026 earnings call, industry prescription data (e.g., IQVIA). | Google Trends: 'Orforglipron' search volume, 'oral weight loss medication' search volume. News sentiment analysis for Orforglipron. | IQVIA: New-to-brand prescriptions (NBRx) for Orforglipron. Symphony Health: Prescription data and market share. |
Key Reported Metrics, Reratings Triggers & ResultsTotal revenue growth is the primary indicator of Lilly's success in its "volume-over-price" transition. Investors will watch if manufacturing scale-up and Medic
| Key reported metrics | Rerating thresholds | ||||
|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date |
| Total Revenue | 43% | Total revenue growth is the primary indicator of Lilly's success in its "volume-over-price" transition. Investors will watch if manufacturing scale-up and Medicare access drive sufficient volume to sustain top-line momentum. | Eli Lilly's Total Revenue needs to report Q2 2026 year-over-year growth of at least 40%, significantly exceeding analyst consensus estimates of approximately $20.5 billion to $20.66 billion. Additionally, the company must reaffirm or, ideally, further raise its recently increased full-year 2026 revenue guidance of $82 billion to $85 billion. | Hitting this threshold validates Lilly's 'volume-over-price' strategy, demonstrating that robust demand for GLP-1 drugs and the successful launch of Foundayo are effectively offsetting pricing pressures. It reinforces the investment thesis of Lilly as a dominant growth play in biopharma, expanding its market share and pipeline, thereby justifying its premium valuation and driving further investor confidence. | |
| US Realized Price Change | -7% | This metric is critical for assessing the financial impact of strategic pricing concessions for Medicare access and China NRDL. It indicates if price erosion is being managed effectively against volume gains. | The US Realized Price Change metric needs to be reported as less negative than the company's guided 'low-to-mid teens' price erosion for 2026. Specifically, a value of -9% or better (i.e., less negative than -9%) would signal that pricing headwinds are being managed more effectively than anticipated, outperforming the expected acceleration from the current -7%. | Achieving a US Realized Price Change better than the guided 'low-to-mid teens' would be a significant positive, indicating that Eli Lilly's 'volume-over-price' strategy is yielding stronger pricing outcomes than expected. This suggests strategic concessions for market access are not leading to as severe price erosion, strengthening the investment thesis by implying higher revenue and margin potential from its dominant GLP-1 franchise. Investors are watching for confirmation that volume growth can more than offset price declines, and a better-than-expected price metric would enhance this outlook. | |
| FDA Approval and US Launch of Orforglipron (Oral GLP-1) | N/A | The approval and launch of Orforglipron are crucial to validate Lilly's market expansion thesis, reaching new patients who prefer oral formulations and potentially expanding the overall obesity market. | FDA approval for Orforglipron (Foundayo) for obesity was achieved on April 1, 2026. For a higher rerating, the US launch needs to demonstrate a significant acceleration in initial prescription (NBRx) ramp, specifically exceeding 50,000 weekly prescriptions within the first 12 weeks post-launch. This would indicate a stronger competitive trajectory against peer oral GLP-1 launches and a clear path towards meeting or exceeding analyst 2026 sales estimates. | Hitting this threshold validates Lilly's market expansion thesis for oral GLP-1s, demonstrating strong patient uptake and competitive positioning against rival oral therapies. It signals that Foundayo is effectively reaching new patients and expanding the overall obesity market, reinforcing Lilly's dominant growth narrative and justifying its premium valuation. | |
Key QuestionsWill Lilly's 'volume-over-price' strategy continue to successfully drive revenue growth in Q2 and Q3 2026, particularly as the July 1 Medicare obesity coverage
Will Lilly's 'volume-over-price' strategy continue to successfully drive revenue growth in Q2 and Q3 2026, particularly as the July 1 Medicare obesity coverage (via the extended bridge program) begins to impact volume and realized prices, offsetting the guided low-to-mid-teen price erosion?
- Question 2
Following the Q2 2026 US launch of Koundeo (oral Orforglipron) and initial positive indicators of market expansion (e.g., 80% new-to-class patients), can Lilly sustain this rapid uptake and broad prescriber adoption, particularly as full-scale consumer promotion begins in Q3, without significant cannibalization of Zepbound?
- Question 3
With positive Phase III data for Retatrutide in type 2 diabetes now reported and an 80-week obesity study readout expected later in Q2 2026, can Lilly continue to demonstrate a superior efficacy and tolerability profile across its remaining Phase 3 trials to solidify Retatrutide's position as a future market leader and extend its GLP-1 pipeline dominance?
Earnings Transcript Summary
· 2025Q4 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. Manufacturing Capacity: Executing a $55 billion build-out to sustain 1.8x annual increases in incretin doses and support global demand. 2. Oral GLP-1 Launch: Preparing for the 2026 US launch of Orforglipron, which management believes will expand the market by reaching patients who prefer orals over injectables. 3. Pipeline Diversification: Reinvesting obesity profits into 'non-obesity' areas, specifically Phase 3 programs in Immunology (Taltz/Zepbound combos) and Oncology (Pirtobrutinib and Imlunestrant). | Tone: Exceptionally Bullish and Aggressive. Takeaway: Lilly is entering a 'volume-over-price' phase where they are willing to accept lower realized prices in exchange for dominant market share and broad access (Medicare/Medicaid). The company is successfully leveraging its obesity franchise to fund a massive R&D expansion, having achieved nearly all clinical milestones in 2025. | Total Revenue: +42%; Key Products: +85%; US Revenue: +46%; Omvo: +50%; Jayperca: +28%; Verzenio: +32%. | 1. Orforglipron Market Dynamics: Analysts questioned if the oral GLP-1 would cannibalize Zepbound. Management responded that early competitor data suggests orals are 'market expansive,' bringing in new patients who were previously on the sidelines. 2. 2026 Pricing Headwinds: Analysts pressed on the guidance for 'low to mid-teens' price declines. Management explained this is a strategic trade-off for massive volume gains through Medicare access and China's NRDL listing. 3. International Growth Sustainability: Analysts asked if the OUS Mounjaro surge was a one-time event. Management clarified that Q4 2025 is the new baseline for 2026, with 75% of OUS revenue coming from the self-pay chronic weight market. | Total Revenue: +43%; Key Products (Mounjaro, Zepbound, etc.): +91%; US Revenue: +43%; OUS Revenue: Double-digit growth in Europe/Japan/China and +100% in Rest of World; Omvo: +55%; Jayperca: +30%; Verzenio: +3%; Kisanlo: $109M (revenue, not y/y growth). |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Lilly is significantly expanding its addressable market through a US government agreement to provide Medicare and Medicaid access to obesity medicines by July 1, 2026, with a $50 out-of-pocket cap. The company is also targeting 'sidelined' patients with the upcoming launch of Orforglipron (oral GLP-1) and expanding into new indications including sleep apnea, osteoarthritis, and psoriatic arthritis. The direct-to-patient platform reached 1 million users, with Zepbound vials making up one-third of new patient starts. | Zepbound maintains a dominant 70% share of new prescriptions in the branded obesity market, while Mounjaro holds over 55% of the US type 2 diabetes incretin market. In neuroscience, Kisanlo has become the US market leader in amyloid-targeting therapies with over 50% share. Management noted that competitor oral launches (oral Wegovy) appear to be market-expansive rather than cannibalistic, validating the demand for oral formulations. | The industry is shifting toward 'consumer centricity' and direct-to-patient delivery models to reduce friction. There is a massive structural build-out in manufacturing, with Lilly committing $55 billion since 2020. Additionally, the integration of AI in drug discovery is accelerating, evidenced by Lilly's new co-innovation lab with NVIDIA and the use of supercomputing to shorten discovery timelines. | Lilly issued 2026 revenue guidance of $80 billion to $83 billion, representing 25% growth. Key milestones include the US launch of Orforglipron for weight management in 2026, six Phase 3 readouts for the triple-agonist Retatrutide, and the expansion of incretins into psychiatry (alcohol use disorder, MDD). The company expects industry-leading volume growth to be partially offset by low-to-mid-teen price erosion due to government access agreements. | Lilly | The 'Consumerization of Pharma' is emerging as a major theme, with subscription-like models and direct-to-consumer digital platforms (LillyDirect) bypassing traditional pharmacy frictions. Another emerging theme is 'Incretins as a Platform,' where metabolic drugs are being tested as foundational treatments for immunology, substance abuse, and psychiatric disorders. | "2025 full-year revenue grew 45% compared to 2024."; "Zepbound continues to be the market leader... with nearly 70% share of new prescriptions."; "Retatrutide... lost an average of 29% of their body weight."; "Kisanlo recently became the US market leader in the amyloid-targeting therapy space." | "Price is expected to be a drag on growth in the low to mid-teens."; "Anticipate a reduction in Medicaid access in 2026 due to key states like California removing obesity coverage."; "Gross margin will be... offset by price and new facilities coming online."; "Overall market penetration has reached a plateau [for Verzenio]." |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Lilly is significantly expanding its addressable market through a US government agreement to provide Medicare and Medicaid access to obesity medicines by July 1, 2026, with a $50 out-of-pocket cap. The company is also targeting 'sidelined' patients with the upcoming launch of Orforglipron (oral GLP-1) and expanding into new indications including sleep apnea, osteoarthritis, and psoriatic arthritis. The direct-to-patient platform reached 1 million users, with Zepbound vials making up one-third of new patient starts. | Zepbound maintains a dominant 70% share of new prescriptions in the branded obesity market, while Mounjaro holds over 55% of the US type 2 diabetes incretin market. In neuroscience, Kisanlo has become the US market leader in amyloid-targeting therapies with over 50% share. Management noted that competitor oral launches (oral Wegovy) appear to be market-expansive rather than cannibalistic, validating the demand for oral formulations. | The industry is shifting toward 'consumer centricity' and direct-to-patient delivery models to reduce friction. There is a massive structural build-out in manufacturing, with Lilly committing $55 billion since 2020. Additionally, the integration of AI in drug discovery is accelerating, evidenced by Lilly's new co-innovation lab with NVIDIA and the use of supercomputing to shorten discovery timelines. | Lilly issued 2026 revenue guidance of $80 billion to $83 billion, representing 25% growth. Key milestones include the US launch of Orforglipron for weight management in 2026, six Phase 3 readouts for the triple-agonist Retatrutide, and the expansion of incretins into psychiatry (alcohol use disorder, MDD). The company expects industry-leading volume growth to be partially offset by low-to-mid-teen price erosion due to government access agreements. | Lilly | The 'Consumerization of Pharma' is emerging as a major theme, with subscription-like models and direct-to-consumer digital platforms (LillyDirect) bypassing traditional pharmacy frictions. Another emerging theme is 'Incretins as a Platform,' where metabolic drugs are being tested as foundational treatments for immunology, substance abuse, and psychiatric disorders. | "2025 full-year revenue grew 45% compared to 2024."; "Zepbound continues to be the market leader... with nearly 70% share of new prescriptions."; "Retatrutide... lost an average of 29% of their body weight."; "Kisanlo recently became the US market leader in the amyloid-targeting therapy space." | "Price is expected to be a drag on growth in the low to mid-teens."; "Anticipate a reduction in Medicaid access in 2026 due to key states like California removing obesity coverage."; "Gross margin will be... offset by price and new facilities coming online."; "Overall market penetration has reached a plateau [for Verzenio]." |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Lilly is expanding its addressable market through a US government agreement for Medicare and Medicaid access to obesity medicines by July 1, 2026, with a $50 out-of-pocket cap. The company is targeting 'sidelined' patients with the upcoming launch of Orforglipron (oral GLP-1) and expanding into new indications including sleep apnea, osteoarthritis, psoriatic arthritis, substance use disorders, bipolar disorder, and major depressive disorder. The direct-to-patient platform reached 1 million users in 2025, with Zepbound self-pay vials making up one-third of new patient starts. Mounjaro has launched in new international markets and is now the incretin share of market leader outside the US. Jayperca received an expanded US indication for people previously treated with a covalent BTK inhibitor, and pirtobrutinib received full FDA approval with an expanded indication for relapsed/refractory CLL, SLL. | Zepbound maintains a dominant 70% share of new prescriptions in the branded obesity market, while Mounjaro holds over 55% of new prescriptions in the US type two diabetes incretin market and is now the incretin share of market leader outside the US. Kisanlo became the US market leader in amyloid-targeting therapy with over 50% share of total prescriptions. Management noted that competitor oral launches (oral Wegovy) appear to be market-expansive rather than cannibalistic, validating the demand for oral formulations. Pirtobrutinib showed compelling risk reduction in CLL/SLL compared to bendamustine plus rituximab and non-inferiority to ibrutinib. Oloralintide demonstrated excellent tolerability, potentially benefiting patients who cannot tolerate incretins. | The industry is shifting toward 'consumer centricity' and direct-to-patient delivery models to reduce friction. There is a massive structural build-out in manufacturing, with Lilly committing over $55 billion since 2020. The integration of AI in drug discovery is accelerating, evidenced by Lilly's new co-innovation AI lab with NVIDIA and the use of supercomputing. There is a growing body of evidence supporting the recognition of obesity as a chronic disease. | Lilly issued 2026 revenue guidance of $80 billion to $83 billion, representing 25% growth, driven by industry-leading volume growth partially offset by low to mid-teens price erosion. The US launch of Orforglipron for chronic weight management is expected in 2026, with international launches in 2027. New Medicare access to obesity medicines is anticipated no later than July 1, 2026. Six additional Phase 3 trials for retreutide are expected to read out in 2026, with submissions for overweight/obesity, obstructive sleep apnea, and knee osteoarthritis planned for 2026. R&D expenses are expected to scale up in 2026 with 36 active Phase III programs and more new programs, alongside increased marketing, selling, and administrative expenses to support new launches. EPS is projected between $33.50 and $35. | GLP1 | The 'Consumerization of Pharma' is emerging as a major theme, with subscription-like models and direct-to-consumer digital platforms (LillyDirect) bypassing traditional pharmacy frictions. Another emerging theme is 'Incretins as a Platform,' where metabolic drugs are being tested as foundational treatments for immunology, substance abuse, and psychiatric disorders. | "2025 full-year revenue grew 45% compared to 2024." "Zepbound continues to be the market leader... with nearly 70% share of new prescriptions." "Retreutide... lost an average of 29% of their body weight at 68 weeks." "Kisanlo recently became the US market leader in the amyloid-targeting therapy space." "We exceeded our goal to produce 1.8 times the number of incretin doses in 2025 compared to 2024." | "Price is expected to be a drag on growth in the low to mid-teens." "Anticipate a reduction in Medicaid access in 2026 due to key states like California removing obesity coverage." "Gross margin will be... offset by price and new facilities coming online." "Overall market penetration has reached a plateau [for Verzenio]." | Lilly strengthened its leadership team with the addition of two new executives, Carole Ho and Anne White. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-02-04 | Eli Lilly's Q4 2025 earnings reported robust 43% revenue growth, driven by Mounjaro and Zepbound. The company issued a bullish 2026 revenue guidance of $80-$83 billion, anticipating 25% growth despite low-to-mid teens price erosion from Medicare access and China NRDL. Management emphasized a "volume-over-price" strategy, expecting oral Orforglipron (Q2 2026 launch) to expand the market. The stock surged 5.45% (outperforming SPY), indicating strong market confidence in Lilly's growth trajectory and pipeline, despite pricing pressures. | Earnings Transcript | Mixed | +5.45% (vs SPY: +5.29%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| LLY_f0ee4b85 | upcoming acquisition | 2026-02-04 | 2026-12-31 | Completion of the acquisition of Ventix. | This strategic action will add multiple clinical stage assets to Lilly's pipeline, potentially impacting future growth and investor sentiment. | Ticker | 2026-02-04 | earnings_transcript |
| LLY_e5f65ab8 | in 2026 | 2026-01-01 | 2026-12-31 | Anticipated reduction in Medicaid access for obesity coverage in key states like California. | This could negatively impact volume growth and access for a segment of patients, potentially acting as a drag on revenue. | Ticker | 2026-02-04 | earnings_transcript |
| LLY_ab8f04c3 | Later this year | 2026-07-01 | 2026-12-31 | Results from the Phase 3 pirtobrutinib trial, Bruin CLL322, evaluating pirtobrutinib in previously treated CLL/SLL patients. | Successful results could form the basis for an additional regulatory submission later in the year, expanding the potential market for pirtobrutinib in oncology. | Ticker | 2026-02-04 | earnings_transcript |
| LLY_3bb3949c | the next phase three readout | 2026-02-04 | 2026-12-31 | Phase 3 readout of the 8,000-patient EMBER-4 trial for Imlunestrant in adjuvant breast cancer. | Positive data could establish Imlunestrant as a significant treatment option in early breast cancer, expanding its label and revenue potential for Lilly's oncology portfolio. | Ticker | 2026-02-04 | earnings_transcript |
| LLY_13c4f6ae | expect to initiate new phase three programs | 2026-02-04 | 2026-12-31 | Initiation of new Phase 3 programs for two oncology small molecules: tirsolecimid and vepubratinib. | This advances Lilly's oncology pipeline, potentially leading to new treatment options with improved tolerability and efficacy, supporting long-term growth. | Ticker | 2026-02-04 | earnings_transcript |
| LLY_41973547 | in 2026 | 2026-02-04 | 2026-12-31 | Initiation of several more Phase 2 and Phase 3 trials for brenepatide, including a Phase 3 trial for major depressive disorder. | Expands the potential applications of incretins into neuroscience, opening new large markets and diversifying Lilly's pipeline beyond cardiometabolic health. | Ticker | 2026-02-04 | earnings_transcript |
| LLY_84cbeb5e | later this year after the Achieve IV trial is complete | 2026-07-01 | 2026-12-31 | Completion of the US regulatory submission of Orforglipron for type 2 diabetes. | This submission will expand the potential market for Orforglipron into type 2 diabetes, leveraging its oral formulation for broader patient access and revenue generation. | Ticker | 2026-02-04 | earnings_transcript |
| LLY_9d9c78c8 | in 2026 | 2026-02-04 | 2026-12-31 | Readout of six additional Phase 3 trials for Retatrutide, including the core registration package for TRIUMPH (obesity) and Transcend (type 2 diabetes) programs. | These readouts are crucial for the regulatory submission of Retatrutide, which has shown significant weight loss potential and could become a new treatment option for severe obesity and T2D. | Ticker | 2026-02-04 | earnings_transcript |
| LLY_93c0ffad | in 2026 | 2026-02-04 | 2026-12-31 | Regulatory submission of the Core TRIUMPH program results for Retatrutide for overweight, obesity, obstructive sleep apnea, and osteoarthritis of the knee. | This submission initiates the regulatory process for Retatrutide across multiple indications, paving the way for future approvals and market entry, further strengthening Lilly's incretin portfolio. | Ticker | 2026-02-04 | earnings_transcript |
| LLY_2a06adb9 | in 2026 | 2026-02-04 | 2026-12-31 | Top-line results from the Together PSO trial evaluating Taltz and Zepbound in adults with moderate to severe plaque psoriasis and obesity/overweight. | Positive results could demonstrate additional efficacy of incretin combinations in immunology, expanding the utility and market for both Taltz and Zepbound. | Ticker | 2026-02-04 | earnings_transcript |
| LLY_ada93b14 | as we head into the back end of this year and mostly into 2027 | 2026-07-01 | 2027-12-31 | Increased employer opt-in for commercial coverage of obesity medicines. | Expanded commercial coverage will increase access and reimbursement for obesity medicines, driving volume growth and revenue for the broader market. | Theme | 2026-02-04 | earnings_transcript |
| LLY_cf82d1b5 | a few markets late in 2026 | 2026-10-01 | 2026-12-31 | Launch of Orforglipron in a few international markets (e.g., UAE). | This marks the beginning of the international rollout for oral Orforglipron, contributing to global revenue growth and market penetration. | Ticker | 2026-02-04 | earnings_transcript |
| LLY_5dfbe593 | ongoing effort | 2026-02-04 | 2027-12-31 | Gaining Mounjaro reimbursement in additional international countries for type 2 diabetes. | Successful reimbursement efforts will expand access and drive volume growth for Mounjaro in international markets, contributing to OUS revenue. | Ticker | 2026-02-04 | earnings_transcript |